Author of

• 13420

  +

  P1.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 206)

  • Event: WCLC 2015
  • Type: Poster
  • Track: Treatment of Advanced Diseases - NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/07/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)

  • 13480

    +

    P1.01-060 - Value Based Health Care Analysis for Lung Cancer Patients (ID 212)

    09:30 - 09:30  |  Author(s): D. Dumoulin
    • Abstract

    Background:
    ‘Care for Outcome’ is a Value Based Health Care project of Santeon (a cooperation of six leading, top clinical hospitals spread across the Netherlands) in which outcome measures for lung cancer are being measured and reported on a yearly base. In this observational study we report differences in outcome of the 6 participating hospitals.
    
    Methods:
    In this retrospective study, data of all lung cancer patients from the Santeon hospitals who were diagnosed between 1-1-2008 and 31-12-2012 was analysed. Primary endpoint in this analysis is mortality. Logistic regression analysis was performed to identify correlating factors for outcome.
    
    Results:
    Data of 5922 lung cancer patients was collected. Of these, 3584 (61%) patients had stage IIIB or IV disease. Tumour stage, performance status, age, co morbidity and treatment with or without chemotherapy correlated significantly with survival. Of these factors, treatment with or without chemotherapy had the highest correlation The percentage of patients receiving chemotherapy was significantly different between hospitals, ranging from 36% to 59% (mean 47,6%). The median survival of patients treated with or without chemotherapy (excluding those who died within 45 days and therefore passing the ‘immortal time bias’ effect) was 124 (95%CI 116-132) and 295 (95%CI 281-309) days (p<0.001) respectively. The difference persisted after correction for tumour stage, performance state, age and co morbidity.
    
    Conclusion:
    There is a strong variation between hospitals in the percentage of patients with stage IIIB / IV lung cancer receiving chemotherapy. Our data indicate that chemotherapy is an independent prognostic factor for survival. Santeon’s ‘Care for Outcome’ team for lung cancer: Onze Lieve Vrouwe Gasthuis, Amsterdam: A.A.J. Smit, MD PhD, St Lucas Andreas Hospital, Amsterdam: H.J. Smit, MD PhD, Catharina Hospital, Eindhoven: D.W. Dumoulin, MD; B.E.E.M. van den Borne, MD PhD, Medisch Spectrum Twente, Enschede: A.J. Polman MD, Martini Hospital, Groningen: J.W.G. van Putten, MD PhD, Antonius Hospital, Nieuwegein: G.J.M. Herder MD PhD; F.M.N.H. Schramel MD PhD; W.F. van den Bosch PhD, Canisius Hospital, Nijmegen: A. Termeer MD